Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 27;13(6):960.
doi: 10.3390/genes13060960.

The History of Early Breast Cancer Treatment

Judith Ben-Dror  1 , Michal Shalamov  2 , Amir Sonnenblick  1   2
Affiliations
Review

The History of Early Breast Cancer Treatment

Judith Ben-Dror et al. Genes (Basel). .

Abstract

"The story of cancer is the story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception" (Siddhartha Mukherjee). The present review discusses the evolution of early breast cancer (BC) treatment philosophy in the last 50 years and the shift from an emphasis on local therapy to an emphasis on systemic precision treatment options.

Keywords: breast cancer; molecular therapeutics; systemic treatment; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

J.B.-D. and M.S. have no conflict of interest to declare. A.S. declare consulting or advisory roles at Eli lilly, Pfizer, Novartis, Roche, Gilead, and MSD; travel, accommodations, and expenses from Neopharm, Celgene, and Medison; speakers’ bureau at Teva, Roche, Pfizer, and Novartis; and grant support from Novartis and Roche.

Figures

Figure 1
Figure 1
Therapeutic molecular targets in breast cancer. ER (estrogen receptor), SERD (selective estrogen receptor degrader), HER1/2 (human epidermal growth factor receptor 1/2), EGFR (epidermal growth factor receptor), and TROP-2 (trophoblast cell surface antigen 2).
Figure 2
Figure 2
Cell cycle targets of chemotherapy and novel drugs.
See this image and copyright information in PMC

References

    1. Momenimovahed Z., Salehiniya H. Epidemiological Characteristics of and Risk Factors for Breast Cancer in the World. Breast Cancer Targets Ther. 2019;11:151–164. doi: 10.2147/BCTT.S176070. - DOI - PMC - PubMed
    1. Fisher B., Jeong J.-H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation. N. Engl. J. Med. 2002;347:567–575. doi: 10.1056/NEJMoa020128. - DOI - PubMed
    1. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., Jeong J.-H., Wolmark N. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. N. Engl. J. Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152. - DOI - PubMed
    1. Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., et al. Intraoperative Radiotherapy versus External Radiotherapy for Early Breast Cancer (ELIOT): A Randomised Controlled Equivalence Trial. Lancet Oncol. 2013;14:1269–1277. doi: 10.1016/S1470-2045(13)70497-2. - DOI - PubMed
    1. Lagendijk M., van Maaren M.C., Saadatmand S., Strobbe L.J.A., Poortmans P.M.P., Koppert L.B., Tilanus-Linthorst M.M.A., Siesling S. Breast Conserving Therapy and Mastectomy Revisited: Breast Cancer-Specific Survival and the Influence of Prognostic Factors in 129,692 Patients: BCT and Mastectomy Revisited. Int. J. Cancer. 2018;142:165–175. doi: 10.1002/ijc.31034. - DOI - PubMed